AHR and infection: The overall AHR comparing incidence of infection in the BNT162b2 cohort to the mRNA‐1273 cohort—controlling for sex, 10‐year age group, nationality group, number of coexisting conditions, prior infection status, and calendar week of the second vaccine dose—was estimated at 1.03 (95% CI: 1.02–1.05; Table 2A).